Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Persister state-directed transitioning and vulnerability in melanoma.
Chauvistré H, Shannan B, Daignault-Mill SM, Ju RJ, Picard D, Egetemaier S, Váraljai R, Gibhardt CS, Sechi A, Kaschani F, Keminer O, Stehbens SJ, Liu Q, Yin X, Jeyakumar K, Vogel FCE, Krepler C, Rebecca VW, Kubat L, Lueong SS, Forster J, Horn S, Remke M, Ehrmann M, Paschen A, Becker JC, Helfrich I, Rauh D, Kaiser M, Gul S, Herlyn M, Bogeski I, Rodríguez-López JN, Haass NK, Schadendorf D, Roesch A. Chauvistré H, et al. Among authors: kubat l. Nat Commun. 2022 Jun 1;13(1):3055. doi: 10.1038/s41467-022-30641-9. Nat Commun. 2022. PMID: 35650266 Free PMC article.
UV-type specific alteration of miRNA expression and its association with tumor progression and metastasis in SCC cell lines.
Chen IP, Bender M, Spassova I, Henning S, Kubat L, Fan K, Degenhardt S, Mhamdi-Ghodbani M, Sriram A, Volkmer B, Boukamp P, Becker JC, Greinert R. Chen IP, et al. Among authors: kubat l. J Cancer Res Clin Oncol. 2020 Dec;146(12):3215-3231. doi: 10.1007/s00432-020-03358-9. Epub 2020 Aug 31. J Cancer Res Clin Oncol. 2020. PMID: 32865618
Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
Spassova I, Ugurel S, Terheyden P, Sucker A, Hassel JC, Ritter C, Kubat L, Habermann D, Farahpour F, Saeedghalati M, Peiffer L, Kumar R, Schrama D, Hoffmann D, Schadendorf D, Becker JC. Spassova I, et al. Among authors: kubat l. Clin Cancer Res. 2020 May 1;26(9):2257-2267. doi: 10.1158/1078-0432.CCR-19-2244. Epub 2020 Jan 13. Clin Cancer Res. 2020. PMID: 31932494
Conversion of Sox2-dependent Merkel cell carcinoma to a differentiated neuron-like phenotype by T antigen inhibition.
Harold A, Amako Y, Hachisuka J, Bai Y, Li MY, Kubat L, Gravemeyer J, Franks J, Gibbs JR, Park HJ, Ezhkova E, Becker JC, Shuda M. Harold A, et al. Among authors: kubat l. Proc Natl Acad Sci U S A. 2019 Oct 1;116(40):20104-20114. doi: 10.1073/pnas.1907154116. Epub 2019 Sep 16. Proc Natl Acad Sci U S A. 2019. PMID: 31527246 Free PMC article.
T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma.
Farah M, Reuben A, Spassova I, Yang RK, Kubat L, Nagarajan P, Ning J, Li W, Aung PP, Curry JL, Torres-Cabala CA, Hudgens CW, Ugurel S, Schadendorf D, Gumbs C, Little LD, Futreal A, Wistuba II, Prieto VG, Wang L, Wong MK, Wargo JA, Becker JC, Tetzlaff MT. Farah M, et al. Among authors: kubat l. J Invest Dermatol. 2020 Nov;140(11):2146-2156.e4. doi: 10.1016/j.jid.2020.02.031. Epub 2020 Apr 15. J Invest Dermatol. 2020. PMID: 32304704 Free article.
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.
Spassova I, Ugurel S, Kubat L, Zimmer L, Terheyden P, Mohr A, Björn Andtback H, Villabona L, Leiter U, Eigentler T, Loquai C, Hassel JC, Gambichler T, Haferkamp S, Mohr P, Pfoehler C, Heinzerling L, Gutzmer R, Utikal JS, Horny K, Schildhaus HU, Habermann D, Hoffmann D, Schadendorf D, Becker JC. Spassova I, et al. Among authors: kubat l. J Immunother Cancer. 2022 Jan;10(1):e003198. doi: 10.1136/jitc-2021-003198. J Immunother Cancer. 2022. PMID: 35074902 Free PMC article.
Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma.
Lindahl LM, Willerslev-Olsen A, Gjerdrum LMR, Nielsen PR, Blümel E, Rittig AH, Celis P, Herpers B, Becker JC, Stausbøl-Grøn B, Wasik MA, Gluud M, Fredholm S, Buus TB, Johansen C, Nastasi C, Peiffer L, Kubat L, Bzorek M, Eriksen JO, Krejsgaard T, Bonefeld CM, Geisler C, Mustelin T, Langhoff E, Givskov M, Woetmann A, Kilian M, Litman T, Iversen L, Odum N. Lindahl LM, et al. Among authors: kubat l. Blood. 2019 Sep 26;134(13):1072-1083. doi: 10.1182/blood.2018888107. Epub 2019 Jul 22. Blood. 2019. PMID: 31331920 Free PMC article.
SATB1 in Malignant T Cells.
Fredholm S, Willerslev-Olsen A, Met Ö, Kubat L, Gluud M, Mathiasen SL, Friese C, Blümel E, Petersen DL, Hu T, Nastasi C, Lindahl LM, Buus TB, Krejsgaard T, Wasik MA, Kopp KL, Koralov SB, Persson JL, Bonefeld CM, Geisler C, Woetmann A, Iversen L, Becker JC, Ødum N. Fredholm S, et al. Among authors: kubat l. J Invest Dermatol. 2018 Aug;138(8):1805-1815. doi: 10.1016/j.jid.2018.03.1526. Epub 2018 May 8. J Invest Dermatol. 2018. PMID: 29751003 Free article.
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations.
Schaper-Gerhardt K, Gutzmer R, Angela Y, Zimmer L, Livingstone E, Schadendorf D, Hassel JC, Weishaupt C, Remes B, Kubat L, Spassova I, Becker JC. Schaper-Gerhardt K, et al. Among authors: kubat l. Eur J Cancer. 2024 May;202:113984. doi: 10.1016/j.ejca.2024.113984. Epub 2024 Mar 2. Eur J Cancer. 2024. PMID: 38479119 Free article.
12 results